ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,938 | -22.1% | 71,367 | +10.4% | 0.00% | – |
| Q2 2023 | $89,834 | -5.7% | 64,631 | +7.9% | 0.00% | – |
| Q1 2023 | $95,276 | -74.0% | 59,923 | +2.2% | 0.00% | -100.0% |
| Q4 2022 | $365,783 | +678.3% | 58,624 | +759.2% | 0.00% | – |
| Q3 2022 | $47,000 | +95.8% | 6,823 | +90.4% | 0.00% | – |
| Q2 2022 | $24,000 | +50.0% | 3,583 | +1.8% | 0.00% | – |
| Q1 2022 | $16,000 | -11.1% | 3,521 | -1.7% | 0.00% | – |
| Q4 2021 | $18,000 | -57.1% | 3,583 | +3.4% | 0.00% | – |
| Q3 2021 | $42,000 | -42.5% | 3,464 | 0.0% | 0.00% | – |
| Q2 2021 | $73,000 | -26.3% | 3,464 | -2.7% | 0.00% | – |
| Q1 2021 | $99,000 | -2.9% | 3,559 | -9.8% | 0.00% | – |
| Q4 2020 | $102,000 | -74.8% | 3,946 | -56.4% | 0.00% | -100.0% |
| Q3 2020 | $404,000 | -23.2% | 9,052 | -11.6% | 0.00% | -50.0% |
| Q2 2020 | $526,000 | +94.8% | 10,237 | +21.1% | 0.00% | +100.0% |
| Q1 2020 | $270,000 | – | 8,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |